His primary scientific interests are in Immunology, Immunogenicity, Antibody, Virology and Immune system. As part of his studies on Immunology, he frequently links adjacent subjects like Receptor. His Receptor study also includes
His Immunogenicity research includes themes of Hemagglutination Inhibition Tests, Adjuvant, Microbiology and Viruslike particle. His studies deal with areas such as Guinea pig, Pharmacology and Glycoprotein as well as Antibody. His Immunoglobulin G study in the realm of Immune system connects with subjects such as Heterologous.
Louis Fries spends much of his time researching Immunology, Virology, Immunogenicity, Antibody and Vaccination. His study on Immunology is mostly dedicated to connecting different topics, such as Adverse effect. His Immunity research extends to Virology, which is thematically connected.
The Immunogenicity study combines topics in areas such as Titer, Influenza vaccine, Immunization, Adjuvant and Seroconversion. He combines subjects such as Receptor, Guinea pig and Microbiology with his study of Antibody. His study in Vaccination is interdisciplinary in nature, drawing from both Internal medicine and Malaria.
Louis Fries mainly focuses on Virology, Adjuvant, Immunogenicity, Vaccination and Antibody. His Virology study integrates concerns from other disciplines, such as Receptor, Immune system and Glycoprotein. The study incorporates disciplines such as Spleen, Plasmodium falciparum and Vaccine efficacy in addition to Adjuvant.
Vaccination is a primary field of his research addressed under Immunology. His study connects Cardiopulmonary disease and Immunology. His Antibody study combines topics in areas such as Virus and Influenza vaccine.
The scientist’s investigation covers issues in Immunogenicity, Virology, Antibody, Virus and Adjuvant. His Immunogenicity study is related to the wider topic of Immunology. His work in the fields of Immunology, such as Immunization, Respiratory syncytial virus and Vaccination, overlaps with other areas such as Placebo.
While the research belongs to areas of Virology, Louis Fries spends his time largely on the problem of Glycoprotein, intersecting his research to questions surrounding Synthetic immunology, 2019-20 coronavirus outbreak and Cytotoxic T cell. His research integrates issues of Respiratory tract infections, Lower respiratory tract infection, Respiratory system, Disease and Pediatrics in his study of Virus. The study incorporates disciplines such as Spleen and Receptor in addition to Adjuvant.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The role of complement in inflammation and phagocytosis
Michael M Frank;Louis F Fries.
Immunology Today (1991)
Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes.
C G Pommier;S Inada;L F Fries;T Takahashi.
Journal of Experimental Medicine (1983)
Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers
Shelly A. McNeil;Scott A. Halperin;Joanne M. Langley;Bruce Smith.
Clinical Infectious Diseases (2005)
Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy
Louis F. Fries;Daniel M. Gordon;Roberta L. Richards;James E. Egan.
Proceedings of the National Academy of Sciences of the United States of America (1992)
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
Cheryl Keech;Gary Albert;Iksung Cho;Andreana Robertson.
The New England Journal of Medicine (2020)
Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.
Milan Basta;Paul Kirshbom;Michael M. Frank;Louis F. Fries.
Journal of Clinical Investigation (1989)
Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade.
L F Fries;H M Friedman;G H Cohen;R J Eisenberg.
Journal of Immunology (1986)
A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine
Louis F. Fries;Gale E. Smith;Gregory M. Glenn.
The New England Journal of Medicine (2013)
Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2.
Roselyn J. Eisenberg;Manuel Ponce de Leon;Harvey M. Friedman;Louis F. Fries.
Microbial Pathogenesis (1987)
C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I.
Louis F. Fries;Thelma A. Gaither;Carl H. Hammer;Michael M. Frank.
Journal of Experimental Medicine (1984)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: